Pharmacokinetics and organ-distribution of 3h-methotrexate and 3h-methotrexate-human serum albumin conjugates in mice

Chong Kook Kim, Sung Joo Hwang

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

This investigation has been made to elucidate the pharmacokinetics and organ distribution of 3H-methotrexate (MTX) and 3H-MTX-human serum albumin (HSA) conjugate in mice and evaluate the feasibility to develop MTX-HSA conjugate as a useful anticancer delivery system. 3H-MTX-HSA conjugate was synthesized by coupling of 3H-MTX with HSA by carbodiimide reaction using EDC. 3H-MTX (treatment I) and 3H-MTX-HSA conjugates (treatment II) were injected intravenously via tail vein of ICR mice. At the designated time, blood was collected via heart puncture, and 4 mice were sacrificed. The liver, spleen, kidney, and lung were excised, and total radioactivity was measured. The mean plasma total radioactivity declined polyexponentially with a mean terminal half-life of 2.7 days from treatment I, however, the radioactivity declined rapidly for up to 3 days after the dose and decreased very slowly thereafter for up to 21 days after the dose. The mean AUQ in the liver, kidney, spleen, and lung was higher from treatment II than that from treatment 1. It clearly indicated that 3H-MTX-HSA conjugates were more uptaken into the organ than that of 3H-MTX, and 3H-MTX was released slowly from the conjugates. In treatment II, the weighted-average overall drug targeting efficiency(Te) for the liver was higher than in treatment 1 (86.4 vs 67.8% and the weighted-average relative tissue exposure(Re) was 6.4 for the liver. It suggested that administration of 3H-MTX-HSA conjugates might have good targeting ability to the liver.

Original languageEnglish
Pages (from-to)961-970
Number of pages10
JournalDrug Development and Industrial Pharmacy
Volume19
Issue number8
DOIs
Publication statusPublished - 1993 Jan 1

Fingerprint

Pharmacokinetics
Methotrexate
Liver
Radioactivity
Therapeutics
Spleen
Carbodiimides
Kidney
Lung
Inbred ICR Mouse
Serum Albumin
Drug Delivery Systems
methotrexate-serum albumin
Punctures
Blood
Half-Life
Tail
Veins
Tissue
Plasmas

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry

Cite this

@article{699051d670634cf596408e9827332ef5,
title = "Pharmacokinetics and organ-distribution of 3h-methotrexate and 3h-methotrexate-human serum albumin conjugates in mice",
abstract = "This investigation has been made to elucidate the pharmacokinetics and organ distribution of 3H-methotrexate (MTX) and 3H-MTX-human serum albumin (HSA) conjugate in mice and evaluate the feasibility to develop MTX-HSA conjugate as a useful anticancer delivery system. 3H-MTX-HSA conjugate was synthesized by coupling of 3H-MTX with HSA by carbodiimide reaction using EDC. 3H-MTX (treatment I) and 3H-MTX-HSA conjugates (treatment II) were injected intravenously via tail vein of ICR mice. At the designated time, blood was collected via heart puncture, and 4 mice were sacrificed. The liver, spleen, kidney, and lung were excised, and total radioactivity was measured. The mean plasma total radioactivity declined polyexponentially with a mean terminal half-life of 2.7 days from treatment I, however, the radioactivity declined rapidly for up to 3 days after the dose and decreased very slowly thereafter for up to 21 days after the dose. The mean AUQ in the liver, kidney, spleen, and lung was higher from treatment II than that from treatment 1. It clearly indicated that 3H-MTX-HSA conjugates were more uptaken into the organ than that of 3H-MTX, and 3H-MTX was released slowly from the conjugates. In treatment II, the weighted-average overall drug targeting efficiency(Te) for the liver was higher than in treatment 1 (86.4 vs 67.8{\%} and the weighted-average relative tissue exposure(Re) was 6.4 for the liver. It suggested that administration of 3H-MTX-HSA conjugates might have good targeting ability to the liver.",
author = "Kim, {Chong Kook} and Hwang, {Sung Joo}",
year = "1993",
month = "1",
day = "1",
doi = "10.3109/03639049309062994",
language = "English",
volume = "19",
pages = "961--970",
journal = "Drug Development and Industrial Pharmacy",
issn = "0363-9045",
publisher = "Informa Healthcare",
number = "8",

}

Pharmacokinetics and organ-distribution of 3h-methotrexate and 3h-methotrexate-human serum albumin conjugates in mice. / Kim, Chong Kook; Hwang, Sung Joo.

In: Drug Development and Industrial Pharmacy, Vol. 19, No. 8, 01.01.1993, p. 961-970.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacokinetics and organ-distribution of 3h-methotrexate and 3h-methotrexate-human serum albumin conjugates in mice

AU - Kim, Chong Kook

AU - Hwang, Sung Joo

PY - 1993/1/1

Y1 - 1993/1/1

N2 - This investigation has been made to elucidate the pharmacokinetics and organ distribution of 3H-methotrexate (MTX) and 3H-MTX-human serum albumin (HSA) conjugate in mice and evaluate the feasibility to develop MTX-HSA conjugate as a useful anticancer delivery system. 3H-MTX-HSA conjugate was synthesized by coupling of 3H-MTX with HSA by carbodiimide reaction using EDC. 3H-MTX (treatment I) and 3H-MTX-HSA conjugates (treatment II) were injected intravenously via tail vein of ICR mice. At the designated time, blood was collected via heart puncture, and 4 mice were sacrificed. The liver, spleen, kidney, and lung were excised, and total radioactivity was measured. The mean plasma total radioactivity declined polyexponentially with a mean terminal half-life of 2.7 days from treatment I, however, the radioactivity declined rapidly for up to 3 days after the dose and decreased very slowly thereafter for up to 21 days after the dose. The mean AUQ in the liver, kidney, spleen, and lung was higher from treatment II than that from treatment 1. It clearly indicated that 3H-MTX-HSA conjugates were more uptaken into the organ than that of 3H-MTX, and 3H-MTX was released slowly from the conjugates. In treatment II, the weighted-average overall drug targeting efficiency(Te) for the liver was higher than in treatment 1 (86.4 vs 67.8% and the weighted-average relative tissue exposure(Re) was 6.4 for the liver. It suggested that administration of 3H-MTX-HSA conjugates might have good targeting ability to the liver.

AB - This investigation has been made to elucidate the pharmacokinetics and organ distribution of 3H-methotrexate (MTX) and 3H-MTX-human serum albumin (HSA) conjugate in mice and evaluate the feasibility to develop MTX-HSA conjugate as a useful anticancer delivery system. 3H-MTX-HSA conjugate was synthesized by coupling of 3H-MTX with HSA by carbodiimide reaction using EDC. 3H-MTX (treatment I) and 3H-MTX-HSA conjugates (treatment II) were injected intravenously via tail vein of ICR mice. At the designated time, blood was collected via heart puncture, and 4 mice were sacrificed. The liver, spleen, kidney, and lung were excised, and total radioactivity was measured. The mean plasma total radioactivity declined polyexponentially with a mean terminal half-life of 2.7 days from treatment I, however, the radioactivity declined rapidly for up to 3 days after the dose and decreased very slowly thereafter for up to 21 days after the dose. The mean AUQ in the liver, kidney, spleen, and lung was higher from treatment II than that from treatment 1. It clearly indicated that 3H-MTX-HSA conjugates were more uptaken into the organ than that of 3H-MTX, and 3H-MTX was released slowly from the conjugates. In treatment II, the weighted-average overall drug targeting efficiency(Te) for the liver was higher than in treatment 1 (86.4 vs 67.8% and the weighted-average relative tissue exposure(Re) was 6.4 for the liver. It suggested that administration of 3H-MTX-HSA conjugates might have good targeting ability to the liver.

UR - http://www.scopus.com/inward/record.url?scp=0027471639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027471639&partnerID=8YFLogxK

U2 - 10.3109/03639049309062994

DO - 10.3109/03639049309062994

M3 - Article

AN - SCOPUS:0027471639

VL - 19

SP - 961

EP - 970

JO - Drug Development and Industrial Pharmacy

JF - Drug Development and Industrial Pharmacy

SN - 0363-9045

IS - 8

ER -